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Dear Editor,
referring to the publication of Liberman et al.
(1) entitled ‘Hip and non-spine fracture risk
reductions differ among antiresorptive agents:
evidence from randomised controlled trials’,
we question the authors’ conclusion that
‘Results from meta-analyses of fracture risk…
suggest that ALN may be more effective than
certain other antiresorptive agents in the treat-
ment with osteoporosis’, based on their meta-
analysis outcomes that alendronate (ALN)
reduces the risk of hip and non-vertebral frac-
ture by 45–55%, hormone therapy (HT) by
25–36% and risedronate (RIS) by 26–27%.
If the article’s purpose was to summarise
the effects of the currently approved antire-
sorptive therapies (page 1395, 1st paragraph),
only the approved doses for each therapy
should be included in the analysis. As the
approved dose for ALN is 5 mg/day for pre-
vention and 10 mg/day for treatment of oste-
oporosis, patients on ALN 20–40 mg/day
dose should be excluded from the analyses.
The meta-analysis for ALN included studies
in which more than 50% of the ALN patients
were treated with 20–40 mg/day dose (2,3). It
does not appear that the authors addressed
the scientiﬁc rationale for such an inclusion
and its impact in the publication. The discus-
sion on dose selection becomes particularly
important when the authors suggested in the
same article that the pooled effect size includ-
ing the FIT trial was smaller because the
patients used lower dose (5 mg/day) in the
ﬁrst 2 years (P1395, last paragraph).
The inclusion criteria of the clinical trials
for the meta-analysis were inconsistent for the
different therapies. As a result the treatment
beneﬁt the risedronate was underestimated.
Non-osteoporotic patients were excluded
from the meta-analysis for the ALN ‡ 5 mg/
day and ‡ 10 mg/day doses, but in the RIS
trials, patients who were over 80 years of age
with risk factor(s) for fall without conﬁrmed
osteoporosis were included in the analyses.
Note that patients who were over the age of
80 with difﬁculty of standing from a chair
may not necessarily be osteoporotic (4). As
neither ALN nor RIS demonstrated a signiﬁ-
cant treatment effect in patients without osteo-
porosis in the FIT or HIP trials, by including
non-osteoporotic patients in the RIS analysis,
the analysis is likely to underestimate the
treatment effect of risedronate. The outcome
of the sensitivity analysis (Table 3 of the arti-
cle) suggested that it underestimated the risk
ratio reduction hip fracture for RIS by 10%
when including the non-conﬁrmed osteopo-
rotic group.
We believe that the authors may have sim-
pliﬁed their outcomes and interpretation with
their rationale that ‘Meta-analysis provides a
more precise estimate than individual trials
when the results are consistent across pooled
trials’ and ‘This pooled analysis including FIT
(‡ 5 mg/day) is not statistically justiﬁed
(because of the signiﬁcant interaction of
treatment with dose)’. As pointed out by
many authors in the literature, meta-analysis
often ‘mixes apples with oranges’, the out-
comes of the meta-analyses are not always
reliable (5–7). It has been found that in many
cases the outcomes of the meta-analyses later
contradicted the outcomes of larger clinical
trials (8). Further, the reasons for the inclu-
sion/exclusion of a trial should be based on
the clinical diversity of the trials not the
results of the trial. ‘Decisions concerning what
should and should not be combined are inev-
itably subjective, and are not amenable to sta-
tistical solutions but require discussion and
clinical judgment’ (9).
We also note that different statistical meth-
ods were used for different therapies. While the
majority of the outcomes were directly taken
from Cranney et al. (10), which used a v
2 pro-
cedure, Poisson regression methods were used
to update the meta-analyses for the therapies
with new data. As a result, different statistical
methods were used for different therapies. The
rationale for using a different method was not
disclosed in the publication and its impact was
not explored for all agents.
Most importantly, as pointed out by Simon
Richard, in Meta-Analysis in Medicine and
Health Policy (11), the relative efﬁcacy of dif-
ferent agents should not be compared based
on the outcomes from meta-analyses. ‘Such
indirect comparisons are usually not sufﬁ-
cient, because of differences among the stud-
ies with regard to numerous factors such as
patients-selection criteria’ (11). Greater hip
fracture risk ratio reduction was observed in
the ‘fracture arm’ relative to the ‘non-fracture
arm’ in both ALN FIT and RIS HIP trials.
This suggests a signiﬁcant impact of patient
population on treatment efﬁcacy. As patient
selection criteria for ALN, HT and RIS trials
were different, treatment comparisons based
on the outcomes of individual meta-analyses
may not have been appropriate in this publi-
cation.
Other differences between the ALN, HT
and RIS trials included the inconsistent use of
concomitant calcium and/or vitamin D, the
differences in methodology in fracture assess-
ment and classiﬁcation, trial duration, and
the rate of the loss to follow-up – all of which
could contribute to the difference in the
observed risk ratio reduction, if the difference
exists at all. Note that no statistical procedure
was conducted to substantiate any statistical
signiﬁcant difference in efﬁcacy between ther-
apies.
In conclusion, this meta-analysis has major
limitations and therefore its conclusions may
be misleading. The treatment group/dose from
each trial was not selected to reﬂect the objec-
tive. The eligibility criteria for the inclusion of
studies were not clearly deﬁned which resulted
in an inconsistency in trial selection for differ-
ent agents. Different statistical methods were
used to analyse different therapies and the basis
to draw the conclusions was ﬂawed.
We are concerned that this meta-analysis
may not have been performed with the
appropriate level of scientiﬁc rigour and that
guidelines for systematic reviews (9) were not
consistently followed.
Faulted on two grounds, the basic premise
of meta-analysis vs. head-to-head clinical tri-
als and the choice of study and treatment
dose, the outcomes of any meta-analyses
should be reviewed critically. In the present
case, we believe that this meta-analysis was
conducted without the appropriate level of
scientiﬁc rigour or precision and the conclu-
sions may not be supported by its results.
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LETTER
Response to Boonen et al. ‘Assessing the relative efﬁcacy of different
osteoporosis agents based on the outcomes from meta-analyses’
To the Editor:
We welcome the opportunity to respond to the
letter from Drs Boonen et al. (1). They ques-
tioned the validity of our meta-analysis because
it pooled studies that differed in doses of drugs,
patient characteristics, statistical methods, con-
comitant use of calcium and vitamin D,
non-vertebral fracture deﬁnition, trial duration
and proportion of patients lost to follow-up.
Their letter does not mention Dr Boonen’s
own meta-analysis on the same subject in
which the analyses were not adjusted for these
above-mentioned differences between studies,
even though these differences were mentioned
in the article (2). In this context, the remarks
in his letter (1) are inconsistent and con-
tradict his own publication (2). Many of the
above-mentioned issues were addressed in
our original article (3) and are therefore
worth repeating and elaborating on.
As stated in our original article (3) the
conclusions were based on the totality of evi-
dence – not only on meta-analyses of fracture
risk, but also head-to-head trials directly
comparing the effects of drugs on bone den-
sity, and adjusted indirect comparisons of
fracture risk. Below we address speciﬁc points
raised by Drs Boonen et al.
We do not agree with their statement that
‘…only the approved doses…should be
included in the analysis’ (1). Several meta-
analyses have been published previously, but
we selected the series reported by the Osteo-
porosis Research Advisory Group (4) as a
foundation because these researchers used rig-
orous, prespeciﬁed, objective statistical meth-
ods to evaluate possible heterogeneity and to
determine which doses of individual drugs
should be combined (pooled) across trials.
The rationale for considering different doses,
and the methods used to test for heterogene-
ity in treatment effects, were described in
both the earlier meta-analyses (4) and in our
article (3). As stated previously, ‘…it is
important to provide evidence that the heter-
ogeneity is statistically signiﬁcant – otherwise,
the apparent differences may simply be spuri-
ous’ (3). Furthermore, our results and con-
clusions clearly indicate which doses were
included in analyses, allowing readers to draw
their own conclusions.
Drs Boonen et al. question the inclusion of
some studies that used alendronate doses
> 10 mg/day. The footnote to Table 2 of our
article (3) indicates that only 5% of patients
in the analysis of hip fracture risk received
> 10 mg/day. In addition, the rationale for
pooling alendronate doses 10 mg/day and
above was based on statistical tests for hetero-
geneity, as explained earlier (3–5). For both
non-vertebral fractures and bone mineral
density (BMD), alendronate at doses of
> 10 mg/day did not have any additional
effect relative to doses of 10 mg, while doses
of 10 mg and above had superior efﬁcacy to a
dose of 5 mg (5).
Their comment that in other disease areas
meta-analyses sometimes contradict the
results of larger, single clinical trials is not rel-
evant to our article (3), because we used all
available data in the meta-analyses, including
all of the largest trials that have been com-
pleted and was also not considered in Dr
Boonen’s own publication (2). In particular,
others have pointed out the fallacy of
attempting to use a single large trial as a ‘gold
standard,’ especially when the meta-analysis
also includes large trials (6).
We agree with Drs Boonen et al. that ‘deci-
sions concerning what should and should not
be combined … require discussion and clini-
cal judgment’. We used the rigorously con-
ducted earlier meta-analyses (4,5) as a
foundation; all studies included in the meta-
analyses were conducted in postmenopausal
women with well-deﬁned fracture risks (those
with osteoporosis, a prevalent vertebral frac-
ture or fall risks), not ‘mixing them up’ with
analyses of patients without such risks, as was
performed in Dr Boonen’s analysis (2).
We stand by our decision to pool the hip
fracture data from risedronate trials shown in
Table 3 of our paper (3), as no heterogeneity
was found between the two arms of the hip
intervention program (HIP) study and the
overall effect of risedronate was to signiﬁ-
cantly reduce the incidence of hip fracture in
the total population.
Our meta-analysis together with other evi-
dence suggests that there are potentially clini-
cally important differences in anti-fracture
effects between antiresorptive drugs (between
classes and between members of classes) in
patients with a high fracture risk, having a
prevalent vertebral fracture and/or low BMD,
or fall risks. The restriction of drug treatment
to patients with well-deﬁned fracture risks
and the differences in antifracture effects
between drugs are recognised in guidelines on
osteoporosis (7) and by governmental organi-
sations such as the EMEA (http://www.
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